Spain’s National Markets and Competition Commission has published a Study on the Retail Distribution of Medicine in Spain, where they analyze the various restrictions on competition that plague this market. The study concludes with a series of recommendations to improve efficiency in this sector.
The study finds that Spain’s current legislation imposes several restrictions on accessing, owning and maintaining a business in the drug retail market, causing a negative impact on competition and harming consumers.
The CNMC has, therefore, recommended the elimination of these restrictions on accessing the market: namely, the obligatory minimum distances between pharmacies and health providers; the elimination on restrictions on trading hours and advertising, and easing the requirements for opening a new pharmacy, among others.
Source: CNMC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Pushes Review of CoStar’s Commercial Real Estate Antitrust Case
Jan 31, 2024 by
CPI
UK’s CMA Investigates Ardonagh’s Atlanta Group and Markerstudy Merger
Jan 31, 2024 by
CPI
Greenberg Traurig Grow Financial Regulatory and Compliance Practice
Jan 31, 2024 by
CPI
Dutch Regulator Fines Uber €10 Million for Privacy Violations
Jan 31, 2024 by
CPI
DOJ Investigates AI Competition, Eyes Microsoft’s OpenAI Deal: Bloomberg
Jan 31, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Rule(s) of Reason
Jan 29, 2024 by
CPI
Evolving the Rule of Reason for Legacy Business Conduct
Jan 29, 2024 by
CPI
The Object Identity
Jan 29, 2024 by
CPI
In Praise of Rules-Based Antitrust
Jan 29, 2024 by
CPI
The Future of State AG Antitrust Enforcement and Federal-State Cooperation
Jan 29, 2024 by
CPI